http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101456696-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y203-02013 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2012-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101456696-B1 |
| titleOfInvention | A method of screening for anti-renal cell carcinoma drug by using TGase2 and p53 |
| abstract | The present invention relates to a method for screening a TGase2 inhibitor or a renal cancer anticancer agent comprising the step of comparing the level of a TGase2 protein and a p53 protein monomer or polymer to a control. Specifically, in the screening method, the TGase2 inhibitor candidate substance is treated with the TGase2-expressing cell, or the kidney cancer cell cancer candidate substance is treated with the kidney cancer cell, and the level of the TGase2 protein and the p53 protein monomer or polymer expressed from the cell In the case where the level of the p53 protein monomer is increased or the level of the polymer is decreased as compared with the control, the separated TGase2 protein and the isolated p53 protein are used in the case of screening for renal cancer chemotherapy by the method of judging the TGase2 inhibitor or the kidney cancer anticancer agent, respectively Thereby screening the renal cancer anticancer agent. |
| priorityDate | 2012-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 437.